Early onset of efficacy with erenumab in patients with episodic and chronic migraine

BACKGROUND: Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM). Early efficacy of migraine preventive medications is an importa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Headache Pain
Autors principals: Schwedt, Todd, Reuter, Uwe, Tepper, Stewart, Ashina, Messoud, Kudrow, David, Broessner, Gregor, Boudreau, Guy P., McAllister, Peter, Vu, Thuy, Zhang, Feng, Cheng, Sunfa, Picard, Hernan, Wen, Shihua, Kahn, Joseph, Klatt, Jan, Mikol, Daniel
Format: Artigo
Idioma:Inglês
Publicat: Springer Milan 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6755616/
https://ncbi.nlm.nih.gov/pubmed/30276500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-018-0923-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars